Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

141. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies

How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies Ferko NC, Borisova N, Airia P, Grima DT, Thompson MF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to explore the effect of varying rebates, co-payments and delivery of drugs (oral or intravenous) on the cost-effectiveness of osteoporosis treatment, for managed care organisations. The authors concluded that the cost-effectiveness of the drugs varied considerably when these factors were

NHS Economic Evaluation Database.2012

142. Vitamin D supplementation in patients with osteoporosis

Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vitamin D supplementation in patients with osteoporosis. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions The purpose (...) of vitamin D supplementation is to improve bone and muscle health, thereby reducing the risk of osteoporosis-related fractures. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Bone Densitys; Dietary Supplements; Osteoporosis; Vitamin D; Vitamins Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200

Health Technology Assessment (HTA) Database.2012

143. Fracture risk and zoledronic acid therapy in men with osteoporosis.

Fracture risk and zoledronic acid therapy in men with osteoporosis. 23113482 2012 11 01 2012 11 13 2017 02 09 1533-4406 367 18 2012 11 01 The New England journal of medicine N. Engl. J. Med. Fracture risk and zoledronic acid therapy in men with osteoporosis. 1714-23 10.1056/NEJMoa1204061 Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men (...) with osteoporosis. In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. The rate

NEJM2012

144. Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of Osteoporosis: assessing the risk of fr fragility fr agility fracture acture Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg146 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osteoporosis: assessing the risk of fragility fracture (CG146) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents

National Institute for Health and Clinical Excellence - Clinical Guidelines2012

145. Osteoporosis

Osteoporosis Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2018 - American College of Obstetricians and Gynecologists

American College of Obstetricians and Gynecologists2012

146. Osteoporosis in Men

Osteoporosis in Men Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation (...) Article navigation 1 June 2012 Article Contents Article Navigation Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline Nelson B. Watts 1 Mercy Health Osteoporosis & Bone Health Services (N.B.W.), Cincinnati Ohio 45236 Search for other works by this author on: Robert A. Adler 2 McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine (R.A.A.), Richmond, Virginia 23298 Search for other works by this author on: John P. Bilezikian 3 Columbia

The Endocrine Society2012

147. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference with dentistry's premier charitable organization (...) oral health website Evidence Education About * Associated Topics Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered

ADA Center for Evidence-Based Dentistry2011

148. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make (...) health website Evidence Education About * Associated Topics Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate

ADA Center for Evidence-Based Dentistry2011

149. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. BACKGROUND: The best strategies to screen postmenopausal women for osteoporosis are not clear. OBJECTIVE: To identify the cost-effectiveness of various screening strategies. DESIGN: Individual-level state-transition cost-effectiveness model. DATA SOURCES: Published literature. TARGET POPULATION: U.S. women aged 55 years or older. TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Screening (...) strategies composed of alternative tests (central dual-energy x-ray absorptiometry [DXA], calcaneal quantitative ultrasonography [QUS], and the Simple Calculated Osteoporosis Risk Estimation [SCORE] tool) initiation ages, treatment thresholds, and rescreening intervals. Oral bisphosphonate treatment was assumed, with a base-case adherence rate of 50% and a 5-year on/off treatment pattern. OUTCOME MEASURES: Incremental cost-effectiveness ratios (2010 U.S. dollars per quality-adjusted life-year [QALY

Annals of Internal Medicine2011 Full Text: Link to full Text with Trip Pro

150. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines

Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Canadian Agency for Drugs (...) and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH

Health Technology Assessment (HTA) Database.2011

152. Whole-body vibration therapy for osteoporosis: state of the science.

Whole-body vibration therapy for osteoporosis: state of the science. Clinical guidelines for osteoporosis recommend dietary and pharmacologic interventions and weight-bearing exercise to prevent bone fractures. These interventions sometimes have low adherence and can cause adverse effects. A proposed alternative or adjunctive treatment is whole-body vibration therapy (WBV), in which energy produced by a forced oscillation is transferred to an individual from a mechanical vibration platform (...) . Whole-body vibration platforms are not approved by the U.S. Food and Drug Administration for medical purposes. This review provides a broad overview of important issues related to WBV therapy for prevention and treatment of osteoporosis. Relying on key informants and a search of the gray and published literature from January 2000 to August 2011, the investigators found that the designs of WBV platforms and protocols for their use vary widely. The optimal target population for the therapy

Annals of Internal Medicine2011

153. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis

The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis Jansen JP, Bergman GJ, Huels J, Olson M CRD summary The review (...) concluded that, in women with osteoporosis, zoledronic acid had the highest probability of preventing vertebral fractures and was comparable with alendronate in preventing hip fractures; risedronate was superior in preventing non-vertebral and non-hip fractures. The potential for biases within the review and the uncertain quality of included trials mean that caution is warranted when interpreting the authors’ conclusions. Authors' objectives To evaluate the efficacy of available bisphosphonates

DARE.2011

154. Calcium carbonate + cholecalciferol (Kalcipos-D®) - Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency

Calcium carbonate + cholecalciferol (Kalcipos-D®) - Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency Published 08 August 2011 Product Update calcium carbonate equivalent to 500mg calcium, cholecalciferol (vitamin D 3 ) 800 IU (20 microgram) tablets (Kalcipos-D 500mg/800 IU chewable tablets®) (No: 718/11 ) Meda Pharmaceuticals Ltd 08 July 2011 The Scottish Medicines Consortium (SMC) has completed its (...) assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission calcium carbonate and cholecalciferol (Kalcipos-D®) is accepted for use within NHS Scotland. Indications under review: ? Prevention and treatment of calcium and vitamin D deficiency in the elderly. ? Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who

Scottish Medicines Consortium2011

155. The societal burden of poor persistence to treatment of osteoporosis in Sweden

The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden Landfeldt E, Lundkvist J, Strom O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the societal burden of poor maintenance of prescribed treatments for osteoporosis and the cost-effectiveness of improving adherence. The authors concluded that poor persistence with the treatment of osteoporosis was an important and costly health burden, and it should be considered when evaluating interventions. Some key assumptions were made, but the methods were valid and the authors

NHS Economic Evaluation Database.2011

156. Osteoporosis.

Osteoporosis. In the clinic. Osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21727287 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order (...) articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jul 5;155(1):ITC1-1-15; quiz ITC1-16. doi: 10.7326/0003-4819-155-1-201107050-01001. In the clinic. Osteoporosis. . PMID: 21727287 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed Simple NCBI Directory Getting Started

Annals of Internal Medicine2011

157. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of denosumab compared with various oral treatments for osteoporosis in postmenopausal women. The authors concluded that denosumab was a cost-effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture, who were not expected to fully adhere to oral treatment. On the whole

NHS Economic Evaluation Database.2011

158. Bazedoxifene (Conbriza)and osteoporosis

Bazedoxifene (Conbriza)and osteoporosis 2011. DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis Content tools Share it For every 5 radiological vertebral fractures avoided there is one case of thromboembolism Bazedoxifene is indicated in postmenopausal osteoporosis in women at increased

Drug and Therapeutics Bulletin of Navarre (Spain)2011

159. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study.

Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. OBJECTIVE: To investigate associations between long term dietary intake of calcium and risk of fracture of any type, hip fractures, and osteoporosis. DESIGN: A longitudinal and prospective cohort study, based on the Swedish Mammography Cohort, including a subcohort, the Swedish Mammography Cohort Clinical. SETTING: A population based cohort in Sweden established in 1987. PARTICIPANTS: 61,433 (...) women (born between 1914 and 1948) were followed up for 19 years. 5022 of these women participated in the subcohort. MAIN OUTCOME MEASURES: Primary outcome measures were incident fractures of any type and hip fractures, which were identified from registry data. Secondary outcome was osteoporosis diagnosed by dual energy x ray absorptiometry in the subcohort. Diet was assessed by repeated food frequency questionnaires. RESULTS: During follow-up, 14,738 women (24%) experienced a first fracture of any

BMJ2011 Full Text: Link to full Text with Trip Pro